Home » Topics » Regulatory » EMA

EMA
RSS

EMA's COMP recommends orphan status for DR Cysteamine in cystinosis

June 16, 2010

European Commission extends indication of RoActemra

June 10, 2010

Sunesis receives scientific advice from EMA on voreloxin program

June 3, 2010

EMA considers postapproval commitment fulfilled for Ceplene/IL-2 in AML

June 2, 2010

Wyeth Europa notifies EMA of withdrawal of MAA for Brilence

June 1, 2010

FDA and EMA approve reanalysis of images from phase III RG-1068 trial

May 31, 2010

Prolia obtains marketing authorization in E.U.

May 31, 2010

Vaxon's Vx-001 to advance from phase I/II to phase III in NSCLC

May 21, 2010

EMA issues positive opinion for orphan status of AEZS-108 in ovarian cancer

May 19, 2010

CHMP adopts positive opinion for variation to terms of Reyataz marketing authorization

April 28, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...